FAQ: The Strategic and Regulatory Logic Behind Biopharma M&A, From Deal Pricing to IND Sponsorship

A pipeline acquisition buys a clinical or commercial asset for its therapeutic value, whereas a platform acquisition buys an operating business—often manufacturing, tools, or service infrastructure—to fold into the buyer's existing commercial footprint. To illustrate, argenx's purchase of Forte Biosciences in July 2026 fits the pipeline acquisition model. It secures a single program, FB102, an anti-CD122 antibody with phase 1b data in vitiligo and celiac disease and follows a prior minority investment argenx had already made in Forte.¹ This acquisition represents a staged, data-driven de-risking strategy in which an early equity stake funds a trial readout, and a full buyout follows only if the data holds up. Repligen's purchase of BioLife Solutions, also in July 2026, fits the platform acquisition model. This deal combines BioLife's CryoStor biopreservation media business with Repligen's existing bioprocessing tools portfolio, adding a high-margin, recurring-revenue franchise rather than a single drug candidate². That distinction shapes how each deal is priced, protected, and reviewed by regulators.